In persons with hepatitis C virus (HCV) infection, HIV coinfection leads to faster progression to advanced liver disease. The aim of our study was to estimate diagnosed HIV prevalence among people with evidence of current HCV infection (polymerase chain reaction positive) and examine predictors of coinfection.
Introduction
In the UK, an estimated 214 000 persons are chronically infected with hepatitis C virus (HCV) and 101 200 are living with HIV [1, 2] . Within the UK, the highest prevalence of HCV infection is reported among persons who inject drugs (PWID), while the highest prevalence rates of HIV infection are among men who have sex with men (MSM) and persons of black African ethnicity [2] .
The prevalence of HCV antibodies (anti-HCV), a marker of ever being infected, in HIV-positive MSM in England was noted to be 4.1% in 2002-2003 and 7.1% in 2008-2009 [12, 13] . Furthermore, the UK Collaborative HIV Cohort (UK CHIC) study estimated HCV prevalence for HIV-positive persons in 2011 at 10.0% overall, corresponding to an estimated 10 000 people, and 9.9% in HIV-positive MSM, compared with 83.3% in HIV-positive PWID [14] . However, these estimates, along with those from other studies [8, 15, 16] , have used HIV-infected individuals as the base population and there has been less focus on HIV prevalence among persons who are HCV positive in the UK. Dougan et al. found that 0.8% of persons with HCV infection were diagnosed with HIV infection when they matched laboratory-confirmed HCV cases between 1996 and 2003 to the national HIV database, although the authors acknowledged that it was probably an underestimate given that the majority of reported cases from genitourinary medicine (GUM) clinics were missing personal identifiers [12] , and Barclay et al. [17] found that 6.5% of patients being treated for HCV infection between 2012 and 2014 were coinfected with HIV. Using a large sentinel surveillance database linked to the national HIV database, we estimated HIV coinfection among persons with evidence of current HCV infection and examined risk factors associated with diagnosed coinfection.
Methods

HCV data
The Sentinel Surveillance of Blood Borne Virus Testing (SSBBV), held at Public Health England (PHE), collects information on hepatitis A-E virus, HIV and human T-lymphotropic virus (HTLV) tests, regardless of result, from 23 participating sentinel laboratories in England. It is estimated to cover 40% of HCV and HIV testing in England. Alongside the test result, SSBBV collects information on demographics and the service requesting the test. The methods have previously been described but, in brief, data from participating laboratory information systems in England were extracted and records of individuals were deduplicated and linked to all other test results using a combination of soundex (phonetic algorithm for indexing names), date of birth, National Health Service (NHS) number and hospital number. Demographic and testing data on all anti-HCV, combined antibody/antigen and polymerase chain reaction (PCR) testing between January 2008 and December 2014 were extracted from SSBBV. Tests were excluded if they were quality control samples, tests to confirm a previous diagnosis, from persons participating in a study and/or from persons < 15 years of age when first tested.
All persons with an HCV antibody or combined antibody/antigen test within the period were included in the study, and an overall 'anti-HCV result' was assigned based on the combination of HCV tests and results recorded for each testing episode. A person's first positive anti-HCV test (indicative of ever being infected with HCV), requester service and first subsequent HCV PCR test (to confirm current infection) were identified.
HIV data
Two PHE data sources were used to identify HIV-positive persons: SSBBV and the HIV and AIDS Reporting System (HARS), which collects information on persons diagnosed with HIV infection and any subsequent access to care at an NHS HIV service in England. From SSBBV, all positive HIV antibody tests were extracted and a person's first positive test date was identified. The HARS data sets were linked to SSBBV using deterministic (where identifiers have to match exactly) and probabilistic (which scores matches using weighted probabilities) methodology. Identifiers used for linkage included hospital number, GUM number, soundex, first name initial, date of birth, sex and region of test. Of persons identified as HIV positive, 60.6% were identified from HARS only, 34.3% from SSBBV and HARS, and 5.1% from SSBBV only. Following data linkage, the earliest date of HIV presentation between the two data sources was established and appended to the HCV testing records. Route of HIV transmission was only available for persons identified as HIV positive from the HARS database, as route of HIV transmission is not recorded in SSBBV.
Definitions
Persons who tested positive for anti-HCV were regarded to have ever been infected with HCV, and persons who tested HCV PCR positive (i.e. were viraemic) were regarded to have a current HCV infection.
To ensure concurrent coinfection, as around 25% will spontaneously clear their HCV infection (the majority in the first 6 months) and persons may have been treated for their HCV [18] , persons were defined as coinfected at the time of HCV diagnosis if there was evidence of an HIV diagnosis at any time prior to their anti-HCV test, or they were newly diagnosed with HIV infection in the 6 months following their anti-HCV test, and they were subsequently identified as HCV PCR positive.
Fisher's exact tests being used to compare categorical variables and Wilcoxon rank-sum tests to compare continuous variables. Predictors of diagnosed coinfection in persons with a current HCV infection were examined using a multivariate logistic regression, which included sex, age at date of anti-HCV test (continuous), ethnicity (including where not reported, as the majority of people testing in sexual health services do not have an ethnicity reported), year of positive anti-HCV test and speciality requesting their anti-HCV test (excluding HIV specialist services). All proportions reported in the text exclude unknowns.
Results
Between 2008 and 2014, 1 368 424 persons aged ≥ 15 years were tested for anti-HCV in the SSBBV network, of whom 2.6% (35 682) were positive, indicative of a person ever having been HCV infected (current or past infection) ( Table 1 ; Fig. 1 ). Overall, 4.4% (1560/ 35 682) of persons who had ever been infected with HCV had also been diagnosed with HIV infection. Of persons ever HCV infected and diagnosed with HIV infection, most were male (84.3%), of white ethnicity (66.9%) and tested for HCV in a sexual health service (67.1%). A higher prevalence of HIV infection was found in men than women (5.6% versus 2.0%, respectively; P < 0.001). Persons of black ethnicity had a higher prevalence, and persons of Asian ethnicity had a lower prevalence of HIV infection, when compared with persons of white ethnicity (9.6% versus 4.5%; P < 0.001 and 1.9 versus 4.5%; P < 0.001, respectively). (20 088). Among those with a current HCV infection, 5.0% (999) had been diagnosed with HIV infection at any time prior to or in the 6 months following their anti-HCV test (coinfected). Persons coinfected were mostly male (87.8%), of white ethnicity (70.6%), tested for HCV at a sexual health service (67.3%) and slightly younger at HCV diagnosis than those with current HCV infection only (median 38 versus 40 years, respectively; P < 0.001).
The highest prevalence of coinfection was among men (6.3%) and persons aged between 30 and 54 years (5.3%). Prevalence of coinfection was lower in persons of Asian ethnicity compared with persons of white ethnicity (2.1 versus 5.1%; P < 0.001). Prevalence varied by speciality, with the highest prevalence of coinfection among persons found to be infected with HCV at a sexual health service (31.9%), followed by persons tested at speciality liver services (6.8%) and at emergency departments (5.6%).
Route of HIV transmission was available for 80.7% (796) of coinfected persons, with the most frequent route of transmission for HIV being sex between men (520; 65.3%), followed by injecting drug use (175; 22.0%) and heterosexual contact (97; 12.2%). Of those where route of transmission was reported as sex between men, 3.1% [16] were also reported to have injected drugs. A higher proportion of coinfected women acquired HIV through injecting drug use than men (44.3% versus 18.9%, respectively; P < 0.001). Regardless of probable route of HIV infection, the majority of persons had their first positive HCV test in a sexual health service.
Of those coinfected, 65.5% were diagnosed with HIV infection > 6 months before their HCV diagnosis, 18.2% were diagnosed with HIV infection in the 6 months before their HCV diagnosis, and 11.5% were diagnosed with HCV and HIV infections on the same day (Fig. 1) . It was found that 4.8% were diagnosed with HIV infection in the 6 months after their HCV diagnosis. In coinfected men and women, 66.8% and 57.8%, respectively, had their HIV infection diagnosed > 6 months before their HCV infection.
Of persons with an HIV diagnosis > 6 months before their positive anti-HCV test, 41.4% (271/654) had a negative anti-HCV test between their HIV and HCV diagnoses between 2008 and 2014. Where route of infection was reported (88.2%), 95.8% (n = 229) acquired their HIV infection following sex between men.
Factors associated with diagnosed coinfection
In a multivariable model, persons with a current HCV infection were more likely to be diagnosed as coinfected if they were male [adjusted odds ratio (aOR) 3.29; 95% confidence interval (CI) 2.60-4.16] or of black ethnicity (aOR 3.19; 95% CI 1.36-7.46); diagnosed coinfection was less likely among older adults (aOR 0.85 per 10-year age increment; 95% CI 0.79-0.92) and among persons of Asian ethnicity (aOR 0.59; 95% CI 0.41-0.86) ( Table 2 ). Compared with persons tested for HCV in general practice, those tested in sexual health services (aOR 143.50; 95% CI 104.98-196.14), specialist liver services (aOR 7.79; 95% CI 5.40-11.24), emergency departments (aOR 6.03; 95% CI 3.44-10.56) and other secondary care services (aOR 3.71; 95% CI 2.72-5.06) were more likely to be diagnosed as being coinfected.
Testing HIV positive > 6 months after HCV test
Among persons not defined as coinfected at the time of HCV diagnosis, 0.19% (37/19 089) of persons with a current HCV infection were diagnosed with HIV infection > 6 months after their HCV diagnosis, 75.7% (28) of whom were male. Unlike when HIV infection was diagnosed prior to or at the time of diagnosis of HCV infection, most persons (where reported; 54.1%; n = 20) diagnosed with HIV infection > 6 months after their HCV diagnosis reported injecting drug use as their route of HIV transmission (50.0%; n = 10), followed by sex between men (35.0%; n = 7), of whom 2.7% [1] also indicated drug use, and heterosexual contact (15.0%; n = 3).
Discussion
Between 2008 and 2014, 1 in 20 (5%) persons with a current HCV infection was diagnosed with HIV infection either prior to or in the 6 months after HCV diagnosis. Overall, men and persons of black ethnicity were significantly more likely to be diagnosed as coinfected. Most persons meeting our criteria for diagnosed coinfection had been diagnosed with HIV infection > 6 months before their HCV diagnosis; a large proportion of these had also previously tested negative for anti-HCV between 2008 and 2014, suggesting that persons with HIV infection continue to engage in behaviour after their diagnosis that puts them at increased risk of HCV infection.
We found that all persons tested for HCV within SSBBV, regardless of result, had a higher prevalence of diagnosed HIV infection than the national average (2.4% versus 0.2%, respectively); diagnosed prevalence was also higher than that among PWID (0.9%), the main group affected by HCV [2, 19] . Previous estimates of HIV infection among persons ever HCV infected, obtained through linking laboratory-confirmed cases of HCV infection (anti-HCV positive) between 1996 and 2003 to national HIV databases, were significantly lower than our results (0.8% compared with 4.4%, respectively) [12] , but our prevalence of diagnosed coinfection among persons currently HCV infected was similar to that found by Barclay et al. (5.0% versus 6.5%, respectively) [17] . The difference compared with Dougan et al. is likely to be attributable to improved availability of identifiers for matching the two data sets, particularly for those attending sexual health services. While injecting drug use is the predominant risk factor within the UK for HCV infection (around 90% of cases are acquired through this route [20] ), among those coinfected, only a quarter of individuals acquired their HIV infection through injecting drug use. In comparison, a higher proportion (78%) acquired their HIV infection through sexual transmission, of whom 84% acquired it through sex between men. In coinfected women, a higher proportion reported injecting drug use (44%), although women constituted only around 10% of the coinfected population.
When the setting of the test was used as an indicator of likely risk, persons were over 140 times more likely to be diagnosed as coinfected with HIV when testing for HCV in sexual health services. While PWID do frequent sexual health clinics, such services are more likely to be frequented by persons participating in high-risk sexual behaviours [15] . Furthermore, HIV prevalence is known to be low in PWID who access drug services, following the implementation of harm reduction strategies, and such services would also routinely undertake blood-borne virus (BBV) testing in people who report injecting drug use. Using the probable route of infection as recorded through HIV surveillance, 65% of those coinfected reported their risk to be sex between men. Research into HCV infections in HIV-positive MSM has also found relatively low rates of injecting drug use (10-40% of persons coinfected) and reported associations with sexual behaviours, such as condomless anal sex, fisting, frequent partner change and sex under the influence of recreational drugs (psychoactive substances), also known as 'chemsex', and concomitant sexually transmitted infections, but not typically 'conventional' injecting drug use [3, 15, 21] . Testing guidelines are also likely to drive testing within sexual health services, as they recommend regular HCV testing for MSM who are HIV positive or who disclose recreational drug use or 'chemsex' during their consultation [22] . However, in those attending sexual health clinics, injecting drug use may be underreported as the most likely route of transmission as a consequence of not being considered socially acceptable.
Two-thirds of persons diagnosed as coinfected were diagnosed with HIV infection > 6 months before their HCV diagnosis, a significant proportion of whom had previously tested HCV negative, confirming the results of previous studies that identified continued behaviours following an HIV diagnosis that put individuals at increased risk of sexually transmitted infections, including HCV infection [15, 23] . While some HIV-positive MSM modify their risk behaviour (serosorting or only having condomless anal sex with other HIV-positive MSM) in an attempt to prevent onwards transmission [24] , tackling the risk of HCV and other sexually transmitted infections remains a challenge for HIV and sexual health services.
Our findings support the British HIV Association guidelines, which indicate that persons with HIV infection should be tested regularly for HCV, with the majority of persons in our study diagnosed with HCV infection a number of months after their HIV diagnosis. However, it is also important that an HIV test is considered following an HCV diagnosis, although only a small proportion of patients in our study were diagnosed with HIV infection post-HCV diagnosis. Despite an HIV test following an HCV diagnosis being recommended by British HIV Association HIV testing guidelines, only 45% of persons with a positive HCV antibody test within SSBBV who were not already diagnosed with HIV infection received an HIV test in the 6 months following their HCV test [21] . As coinfected persons have faster liver disease progression, it is important that persons are tested for other BBVs once diagnosed with either HCV or HIV infection [6, 7] , and that they continue to be offered tests when reporting behaviours that put them at increased risk of coinfection.
Important limitations to this study include, firstly, the issue that tests within sexual health services have limited patient identifiers and so true matches may have been missed when linking the data sets. Secondly, we have only been able to report on persons diagnosed with HCV and HIV infections; we do not know how coinfection rates differ in persons undiagnosed, which will be influenced by the proportions of undiagnosed HIV and HCV infections in different subpopulations. As heterosexuals have higher rates of undiagnosed HIV infection in England, [2] this is more likely to be an issue among people who acquire HIV through heterosexual sex than among MSM. In addition, there are no guidelines for HCV testing other than in individuals who report injecting drug use or are HIV positive, and populations not covered by these guidelines may be underrepresented in our HCV testing database. Thirdly, as SSBBV is a sentinel system it will not include earlier HCV tests that occurred outside of our centres. This could result in persons who had previously tested positive outside of SSBBV, who were then tested within SSBBV, having a later HCV diagnosis date assigned to them. SSBBV coverage by Local Authorities ranges from 0 to 100%, with higher coverage in urban areas, but on average it is estimated to cover 40% of HCV testing in England. Additionally, we were not able to determine how many people who were not diagnosed with HIV infection had been tested for the infection elsewhere. This would have helped to better understand the potential impact of undiagnosed HIV infection on coinfection prevalence.
We found rates of diagnosed HIV infection in persons with a current HCV infection to be higher than those found in PWID and that most HIV infections were among MSM, indicating that diagnosed coinfection is mainly associated with high-risk sexual behaviour, rather than injecting drug use, the dominant risk factor for those who are HCV monoinfected. As an HIV diagnosis preceded an HCV infection in the majority of those who were coinfected (many of whom would have been engaged in care, have been receiving HIV treatment and have previously tested HCV negative), more needs to be done to increase awareness of HCV infection risk and the need for regular testing and to encourage safer sex, as well as to understand the contribution of 'chemsex' to HCV and HIV infection risk.
